alpha Synuclein antibody, alpha Synuclein Antibody, Rabbit Polyclonal Antibody

Alphabetical Listing of Primary Antibodies:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Alphabetical Listing of Proteins:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Peptides \| Secondary Antibodies \| ELISA Kits

alpha Synuclein Antibody, Rabbit Polyclonal Antibody

Catalog Number: 18-272-196445

Buy alpha Synuclein antibody -

Volume:

Related Product Names:

- alpha Synuclein antibody; alpha Synuclein; 6622; SNCA; 127750; P37840; MGC110988; NACP; PARK1; PARK4; PD1;; alpha Synuclein
- Rabbit polyclonal to alpha Synuclein; 6622; SNCA; 127750; P37840; MGC110988; NACP; PARK1; PARK4; PD1;; Alpha-synuclein

- Gene Information - Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.

Gene Name: alpha Synuclein	Gene Name Synonym: 6622; SNCA; 127750; P37840; MGC110988; NACP; PARK1; PARK4; PD1;
Gi #: N/A	NCBI Acc #: NP_000336.1	Swiss Prot Acc #: P37840
Length (aa): N/A	Mol. Weight (Da): 14460	Chrom Location: N/A

Isotype: IgG

Immunogen: A synthetic peptide corresponding to near C-terminal of human alpha Synuclein (amino acid # 111 - 131).

Antigen Species: Human

Specificity: Specific for alpha synuclein.Does not cross react with beta synuclein.

Positive Control: Posterior cingulated gyrus

Target: alpha Synuclein

Localization: Cytoplasmic and Nuclear. Membrane-bound in dopaminergic neurons.

Concentration: 0.2 mg/ml

Storage Buffer: Phosphate-buffered saline, pH 7.4 containing 1% BSA and 0.09% sodium azide

Application Note: IHC-P: Use at a dilution of 1/100 for 10 min at RT. No special pretreatment is required for the immunohistochemical staining of formalin/paraffin tissues. Not tested in other applications. Optimal dilutions/concentrations should be determined by the end user.

Cellular Localization: Cytoplasmic and Nuclear. Membrane-bound in dopaminergic neurons.

Source/Host: Rabbit

Purity/Purification: Immunogen affinity purified

Clonality: Polyclonal

Crossreactivity: Cross-reacts with Human and Rat. Not yet tested in other species.

Format: Liquid

Storage: Keep as concentrated solution, aliquot and store at 4C. Do not freeze.

Shipping: Products may be shipped on ice pack or dry ice.

APPLICATIONS for ALPHA SYNUCLEIN ANTIBODY:

IHC-P: Tested

TESTING: (secondary reagents and protocols )

Not Available

ALPHA SYNUCLEIN ANTIBODY TARGET DESCRIPTION:

Synonym Names for alpha Synuclein antibody: alpha Synuclein; 6622; SNCA; 127750; P37840; MGC110988; NACP; PARK1; PARK4; PD1;; Rabbit polyclonal to alpha Synuclein; 6622; SNCA; 127750; P37840; MGC110988; NACP; PARK1; PARK4; PD1;; Alpha-synuclein

The implication of alpha synuclein in neurodegenerative diseases started after the identification of non A beta component of amyloid (NAC peptide) in Alzheimer's disease (AD) brains. There is now a general group of synucleinopathies which implicates alpha synuclein in Lewy body syndromes, Parkinson' disease, and Alzheimer's disease. Certain missense mutations in the alpha synuclein gene (A53T, A30P) have been linked to the familial Parkinson's disease (PD). Alpha Synuclein is the major component of Lewy bodies and Lewy neuritis in sporadic PD, dementia with Lewy Bodies and Lewy Body variant of AD. Lewy bodies are composed of truncated and phosphorylated intermediate neurofilament proteins, alpha synuclein, ubiquitin and associated enzymes. The synuclein phosphoproteins (15-20 kD) are small highly conserved proteins in vertebrates. The synuclein family includes alpha and beta synucleins and loosely related gamma synuclein and synoretin. The expression is abundant in neurons and typically is localized at presynaptic terminals. Antibodies to alpha synuclein provide a specific method to detect Lewy bodies and associated pathological mechanism of PD and AD.

Function: May be involved in the regulation of dopamine release and transport. Soluble protein, normally localized primarily at the presynaptic region of axons, which can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies). Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation.

Subunit: Soluble monomer which can form filamentous aggregates. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones.

Subcellular Location: Cytoplasm. Membrane. Nucleus. Note=Membrane-bound in dopaminergic neurons. Also found in the nucleus.

Tissue Specificity: Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.

Domain: The NAC domain is involved in the fibril formation. The middle region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.

Ptm: Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.

Ptm: Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.

Ptm: Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity).

Disease: Defects in SNCA are a cause of autosomal dominant Parkinson disease 1 (PARK1) [MIM:168601, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.

Disease: Defects in SNCA are the cause of Parkinson disease 4 (PARK4) [MIM:605543, 168600].

Disease: Defects in SNCA are the cause of Lewy body dementia (DLB) [MIM:127750]. DLB is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Presence of Lewy bodies are the only essential pathologic features.

Disease: Deposition of fibrillar amyloid proteins intraneuronally as neurofibrillary tangles is characteristic of Alzheimer disease (AD). SNCA is a minor protein found within these deposits, but a major non amyloid component.

Disease: Brain iron accumulation type 1 (NBIA1, also called Hallervorden-Spatz syndrome), a rare neuroaxonal dystrophy, is histologically characterized by axonal spheroids, iron deposition, Lewy body (LB)-like intraneuronal inclusions, glial inclusions and neurofibrillary tangles. SNCA is found in LB-like inclusions, glial inclusions and spheroids.

Similarity: Belongs to the synuclein family.

alpha Synuclein reacts with cross-reacts with human and rat. not yet tested in other species..

OMIM: 127750; phenotype. [NCBI / EBI]
163890; gene. [NCBI / EBI]
168600; phenotype. [NCBI / EBI]
168601; phenotype. [NCBI / EBI]
605543; phenotype. [NCBI / EBI]

Pathways:
KEGG pathway: Alzheimer's disease 05010
KEGG pathway: Neurodegenerative Disorders 01510
KEGG pathway: Parkinson's disease 05020

Products similar to alpha Synuclein antibody:

IgG

pan Synuclein, IgG

alpha Synuclein (ready-to-use), IgG

TGF beta [2C5], IgG

Goat A' alpha-synuclein (C-terminal), IgG

beta Synuclein (ready-to-use), IgG

Peptide

Alpha Synuclein C-terminal Peptide, Peptide

alpha-Synuclein, Protein

alpha-Synuclein A30P, Protein

b-NGF Mouse, Protein

alpha-Synuclein, Protein

SUGGESTED ANITBODY REAGENTS - GenWay has an extensive selection of reagents useful for antibody applications. Find blocking buffers, stop reagents, chemiluminescent substrates, diluents, Immunohistochemistry reagents & more.

Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.

Precautions: alpha Synuclein antibody is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.

Important Notes: During shipment, small volumes of alpha Synuclein antibody vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.

Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about alpha Synuclein antibody, all related information, articles, resources about alpha Synuclein antibody are being stored on our online database. Let us know if you have questions regarding this product.

Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed.

GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.

Thank you for visiting GenWay Biotech's Datasheet. GenWay is the world's leader in chicken, IgY antibody production, producing over 900 quality polyclonal IgY antibodies to date. From our unique recombinant protein production, utilizing a variety of protein expression systems, GenWay's polyclonal IgY antibodies incorporate more epitopes, increasing the success rate for ELISA, western blot, immunohistochemistry (IHC), immunocytochemistry (ICC), and many more immunoassays.



GenWay Biotech, Inc. 6777 Nancy Ridge Drive, San Diego, CA 92121 Tel: (858)458-0866 Fax: (858)458-0833 Email: sales@genwaybio.com www.genwaybio.com ©1998 - 2010 GenWay Biotech, Inc. - All Rights Reserved